Global Novel Vaccine Delivery Systems Market Size, Growth Drivers, Share, Key Players, Competitive Analysis, Trends, Opportunities, Revenue Insights, and Demand Forecast to 2032

Global Novel Vaccine Delivery Systems Market Size, Growth Drivers, Share, Key Players, Competitive Analysis, Trends, Opportunities, Revenue Insights, and Demand Forecast to 2032
Report Category: Pharma and Healthcare
SKU: PMR-121549  Published Date: 2025-02-18   Pages:110   Delivery Format:


CHOOSE LICENSE TYPE





PMR Research.

Market Executive Summary

The global market for Novel Vaccine Delivery Systems was estimated to be worth US$ 7163 million in 2024 and is forecast to a readjusted size of US$ 14540 million by 2031 with a CAGR of 10.8% during the forecast period 2025-2031.

Novel vaccine delivery includes formulations, technologies, methods, and systems to transfer an active pharmaceutical ingredient in the body, as desired, in order to safely accomplish its therapeutic effect.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report aims to provide a comprehensive presentation of the global market for Novel Vaccine Delivery Systems, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Novel Vaccine Delivery Systems by region & country, by Type, and by Application.

The Novel Vaccine Delivery Systems market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Novel Vaccine Delivery Systems.

Global Novel Vaccine Delivery Systems Companies Covered

Altaris Capital Partners, Kindeva Drug Delivery, Becton, Dickinson,, Carl Zeiss Foundation, Gerresheimer AG, Corium International, Inovio Pharmaceuticals, Bioject Medical Technologies, PharmaJet, Retractable Technologies, Terumo Corporation, VAXXAS

Global Novel Vaccine Delivery Systems Market, by Region

North America (U.S., Canada, Mexico)

Europe (Germany, France, UK, Italy, etc.)

Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)

South America (Brazil, etc.)

Middle East and Africa (Turkey, GCC Countries, Africa, etc.)

Global Novel Vaccine Delivery Systems Market, Segment by Type

Intradermal Delivery

Intramuscular Delivery

Others

Global Novel Vaccine Delivery Systems Market, Segment by Application

Hospitals & Clinics

Research Institutes

Others

Chapter Outline

Chapter 1:
Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Novel Vaccine Delivery Systems company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Revenue of Novel Vaccine Delivery Systems in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Revenue of Novel Vaccine Delivery Systems in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Related Reports:

Global Nanotechnology-based Drug Delivery Systems Market Size, Share, Key Players, Competitive Landscape, Growth Drivers, Trends, Opportunities, Revenue Analysis, and Demand Forecast to 2032

Global Chemical Delivery Systems Market Size, Share, Growth Drivers, Trends, Opportunities, Competitive Analysis, and Forecast To 2030



Table of Contents

Table of Contents

 1 Market Overview

    1.1 Novel Vaccine Delivery Systems Product Introduction

    1.2 Global Novel Vaccine Delivery Systems Market Size Forecast (2020-2031)

    1.3 Novel Vaccine Delivery Systems Market Trends & Drivers

        1.3.1 Novel Vaccine Delivery Systems Industry Trends

        1.3.2 Novel Vaccine Delivery Systems Market Drivers & Opportunity

        1.3.3 Novel Vaccine Delivery Systems Market Challenges

        1.3.4 Novel Vaccine Delivery Systems Market Restraints

    1.4 Assumptions and Limitations

    1.5 Study Objectives

    1.6 Years Considered

 2 Competitive Analysis by Company

    2.1 Global Novel Vaccine Delivery Systems Players Revenue Ranking (2024)

    2.2 Global Novel Vaccine Delivery Systems Revenue by Company (2020-2025)

    2.3 Key Companies Novel Vaccine Delivery Systems Manufacturing Base Distribution and Headquarters

    2.4 Key Companies Novel Vaccine Delivery Systems Product Offered

    2.5 Key Companies Time to Begin Mass Production of Novel Vaccine Delivery Systems

    2.6 Novel Vaccine Delivery Systems Market Competitive Analysis

        2.6.1 Novel Vaccine Delivery Systems Market Concentration Rate (2020-2025)

        2.6.2 Global 5 and 10 Largest Companies by Novel Vaccine Delivery Systems Revenue in 2024

        2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Novel Vaccine Delivery Systems as of 2024)

    2.7 Mergers & Acquisitions, Expansion

 3 Segmentation by Type

    3.1 Introduction by Type

        3.1.1 Intradermal Delivery

        3.1.2 Intramuscular Delivery

        3.1.3 Others

    3.2 Global Novel Vaccine Delivery Systems Sales Value by Type

        3.2.1 Global Novel Vaccine Delivery Systems Sales Value by Type (2020 VS 2024 VS 2031)

        3.2.2 Global Novel Vaccine Delivery Systems Sales Value, by Type (2020-2031)

        3.2.3 Global Novel Vaccine Delivery Systems Sales Value, by Type (%) (2020-2031)

 4 Segmentation by Application

    4.1 Introduction by Application

        4.1.1 Hospitals & Clinics

        4.1.2 Research Institutes

        4.1.3 Others

    4.2 Global Novel Vaccine Delivery Systems Sales Value by Application

        4.2.1 Global Novel Vaccine Delivery Systems Sales Value by Application (2020 VS 2024 VS 2031)

        4.2.2 Global Novel Vaccine Delivery Systems Sales Value, by Application (2020-2031)

        4.2.3 Global Novel Vaccine Delivery Systems Sales Value, by Application (%) (2020-2031)

 5 Segmentation by Region

    5.1 Global Novel Vaccine Delivery Systems Sales Value by Region

        5.1.1 Global Novel Vaccine Delivery Systems Sales Value by Region: 2020 VS 2024 VS 2031

        5.1.2 Global Novel Vaccine Delivery Systems Sales Value by Region (2020-2025)

        5.1.3 Global Novel Vaccine Delivery Systems Sales Value by Region (2026-2031)

        5.1.4 Global Novel Vaccine Delivery Systems Sales Value by Region (%), (2020-2031)

    5.2 North America

        5.2.1 North America Novel Vaccine Delivery Systems Sales Value, 2020-2031

        5.2.2 North America Novel Vaccine Delivery Systems Sales Value by Country (%), 2024 VS 2031

    5.3 Europe

        5.3.1 Europe Novel Vaccine Delivery Systems Sales Value, 2020-2031

        5.3.2 Europe Novel Vaccine Delivery Systems Sales Value by Country (%), 2024 VS 2031

    5.4 Asia Pacific

        5.4.1 Asia Pacific Novel Vaccine Delivery Systems Sales Value, 2020-2031

        5.4.2 Asia Pacific Novel Vaccine Delivery Systems Sales Value by Region (%), 2024 VS 2031

    5.5 South America

        5.5.1 South America Novel Vaccine Delivery Systems Sales Value, 2020-2031

        5.5.2 South America Novel Vaccine Delivery Systems Sales Value by Country (%), 2024 VS 2031

    5.6 Middle East & Africa

        5.6.1 Middle East & Africa Novel Vaccine Delivery Systems Sales Value, 2020-2031

        5.6.2 Middle East & Africa Novel Vaccine Delivery Systems Sales Value by Country (%), 2024 VS 2031

 6 Segmentation by Key Countries/Regions

    6.1 Key Countries/Regions Novel Vaccine Delivery Systems Sales Value Growth Trends, 2020 VS 2024 VS 2031

    6.2 Key Countries/Regions Novel Vaccine Delivery Systems Sales Value, 2020-2031

    6.3 United States

        6.3.1 United States Novel Vaccine Delivery Systems Sales Value, 2020-2031

        6.3.2 United States Novel Vaccine Delivery Systems Sales Value by Type (%), 2024 VS 2031

        6.3.3 United States Novel Vaccine Delivery Systems Sales Value by Application, 2024 VS 2031

    6.4 Europe

        6.4.1 Europe Novel Vaccine Delivery Systems Sales Value, 2020-2031

        6.4.2 Europe Novel Vaccine Delivery Systems Sales Value by Type (%), 2024 VS 2031

        6.4.3 Europe Novel Vaccine Delivery Systems Sales Value by Application, 2024 VS 2031

    6.5 China

        6.5.1 China Novel Vaccine Delivery Systems Sales Value, 2020-2031

        6.5.2 China Novel Vaccine Delivery Systems Sales Value by Type (%), 2024 VS 2031

        6.5.3 China Novel Vaccine Delivery Systems Sales Value by Application, 2024 VS 2031

    6.6 Japan

        6.6.1 Japan Novel Vaccine Delivery Systems Sales Value, 2020-2031

        6.6.2 Japan Novel Vaccine Delivery Systems Sales Value by Type (%), 2024 VS 2031

        6.6.3 Japan Novel Vaccine Delivery Systems Sales Value by Application, 2024 VS 2031

    6.7 South Korea

        6.7.1 South Korea Novel Vaccine Delivery Systems Sales Value, 2020-2031

        6.7.2 South Korea Novel Vaccine Delivery Systems Sales Value by Type (%), 2024 VS 2031

        6.7.3 South Korea Novel Vaccine Delivery Systems Sales Value by Application, 2024 VS 2031

    6.8 Southeast Asia

        6.8.1 Southeast Asia Novel Vaccine Delivery Systems Sales Value, 2020-2031

        6.8.2 Southeast Asia Novel Vaccine Delivery Systems Sales Value by Type (%), 2024 VS 2031

        6.8.3 Southeast Asia Novel Vaccine Delivery Systems Sales Value by Application, 2024 VS 2031

    6.9 India

        6.9.1 India Novel Vaccine Delivery Systems Sales Value, 2020-2031

        6.9.2 India Novel Vaccine Delivery Systems Sales Value by Type (%), 2024 VS 2031

        6.9.3 India Novel Vaccine Delivery Systems Sales Value by Application, 2024 VS 2031

 7 Company Profiles

    7.1 Altaris Capital Partners

        7.1.1 Altaris Capital Partners Profile

        7.1.2 Altaris Capital Partners Main Business

        7.1.3 Altaris Capital Partners Novel Vaccine Delivery Systems Products, Services and Solutions

        7.1.4 Altaris Capital Partners Novel Vaccine Delivery Systems Revenue (US$ Million) & (2020-2025)

        7.1.5 Altaris Capital Partners Recent Developments

    7.2 Kindeva Drug Delivery

        7.2.1 Kindeva Drug Delivery Profile

        7.2.2 Kindeva Drug Delivery Main Business

        7.2.3 Kindeva Drug Delivery Novel Vaccine Delivery Systems Products, Services and Solutions

        7.2.4 Kindeva Drug Delivery Novel Vaccine Delivery Systems Revenue (US$ Million) & (2020-2025)

        7.2.5 Kindeva Drug Delivery Recent Developments

    7.3 Becton

        7.3.1 Becton Profile

        7.3.2 Becton Main Business

        7.3.3 Becton Novel Vaccine Delivery Systems Products, Services and Solutions

        7.3.4 Becton Novel Vaccine Delivery Systems Revenue (US$ Million) & (2020-2025)

        7.3.5 Becton Recent Developments

    7.4 Dickinson,

        7.4.1 Dickinson, Profile

        7.4.2 Dickinson, Main Business

        7.4.3 Dickinson, Novel Vaccine Delivery Systems Products, Services and Solutions

        7.4.4 Dickinson, Novel Vaccine Delivery Systems Revenue (US$ Million) & (2020-2025)

        7.4.5 Dickinson, Recent Developments

    7.5 Carl Zeiss Foundation

        7.5.1 Carl Zeiss Foundation Profile

        7.5.2 Carl Zeiss Foundation Main Business

        7.5.3 Carl Zeiss Foundation Novel Vaccine Delivery Systems Products, Services and Solutions

        7.5.4 Carl Zeiss Foundation Novel Vaccine Delivery Systems Revenue (US$ Million) & (2020-2025)

        7.5.5 Carl Zeiss Foundation Recent Developments

    7.6 Gerresheimer AG

        7.6.1 Gerresheimer AG Profile

        7.6.2 Gerresheimer AG Main Business

        7.6.3 Gerresheimer AG Novel Vaccine Delivery Systems Products, Services and Solutions

        7.6.4 Gerresheimer AG Novel Vaccine Delivery Systems Revenue (US$ Million) & (2020-2025)

        7.6.5 Gerresheimer AG Recent Developments

    7.7 Corium International

        7.7.1 Corium International Profile

        7.7.2 Corium International Main Business

        7.7.3 Corium International Novel Vaccine Delivery Systems Products, Services and Solutions

        7.7.4 Corium International Novel Vaccine Delivery Systems Revenue (US$ Million) & (2020-2025)

        7.7.5 Corium International Recent Developments

    7.8 Inovio Pharmaceuticals

        7.8.1 Inovio Pharmaceuticals Profile

        7.8.2 Inovio Pharmaceuticals Main Business

        7.8.3 Inovio Pharmaceuticals Novel Vaccine Delivery Systems Products, Services and Solutions

        7.8.4 Inovio Pharmaceuticals Novel Vaccine Delivery Systems Revenue (US$ Million) & (2020-2025)

        7.8.5 Inovio Pharmaceuticals Recent Developments

    7.9 Bioject Medical Technologies

        7.9.1 Bioject Medical Technologies Profile

        7.9.2 Bioject Medical Technologies Main Business

        7.9.3 Bioject Medical Technologies Novel Vaccine Delivery Systems Products, Services and Solutions

        7.9.4 Bioject Medical Technologies Novel Vaccine Delivery Systems Revenue (US$ Million) & (2020-2025)

        7.9.5 Bioject Medical Technologies Recent Developments

    7.10 PharmaJet

        7.10.1 PharmaJet Profile

        7.10.2 PharmaJet Main Business

        7.10.3 PharmaJet Novel Vaccine Delivery Systems Products, Services and Solutions

        7.10.4 PharmaJet Novel Vaccine Delivery Systems Revenue (US$ Million) & (2020-2025)

        7.10.5 PharmaJet Recent Developments

    7.11 Retractable Technologies

        7.11.1 Retractable Technologies Profile

        7.11.2 Retractable Technologies Main Business

        7.11.3 Retractable Technologies Novel Vaccine Delivery Systems Products, Services and Solutions

        7.11.4 Retractable Technologies Novel Vaccine Delivery Systems Revenue (US$ Million) & (2020-2025)

        7.11.5 Retractable Technologies Recent Developments

    7.12 Terumo Corporation

        7.12.1 Terumo Corporation Profile

        7.12.2 Terumo Corporation Main Business

        7.12.3 Terumo Corporation Novel Vaccine Delivery Systems Products, Services and Solutions

        7.12.4 Terumo Corporation Novel Vaccine Delivery Systems Revenue (US$ Million) & (2020-2025)

        7.12.5 Terumo Corporation Recent Developments

    7.13 VAXXAS

        7.13.1 VAXXAS Profile

        7.13.2 VAXXAS Main Business

        7.13.3 VAXXAS Novel Vaccine Delivery Systems Products, Services and Solutions

        7.13.4 VAXXAS Novel Vaccine Delivery Systems Revenue (US$ Million) & (2020-2025)

        7.13.5 VAXXAS Recent Developments

 8 Industry Chain Analysis

    8.1 Novel Vaccine Delivery Systems Industrial Chain

    8.2 Novel Vaccine Delivery Systems Upstream Analysis

        8.2.1 Key Raw Materials

        8.2.2 Raw Materials Key Suppliers

        8.2.3 Manufacturing Cost Structure

    8.3 Midstream Analysis

    8.4 Downstream Analysis (Customers Analysis)

    8.5 Sales Model and Sales Channels

        8.5.1 Novel Vaccine Delivery Systems Sales Model

        8.5.2 Sales Channel

        8.5.3 Novel Vaccine Delivery Systems Distributors

 9 Research Findings and Conclusion

 10 Appendix

    10.1 Research Methodology

        10.1.1 Methodology/Research Approach

            10.1.1.1 Research Programs/Design

            10.1.1.2 Market Size Estimation

            10.1.1.3 Market Breakdown and Data Triangulation

        10.1.2 Data Source

            10.1.2.1 Secondary Sources

            10.1.2.2 Primary Sources

    10.2 Author Details

    10.3 Disclaimer



List of Figures

Table of Figures

List of Tables

 Table 1. Novel Vaccine Delivery Systems Market Trends

 Table 2. Novel Vaccine Delivery Systems Market Drivers & Opportunity

 Table 3. Novel Vaccine Delivery Systems Market Challenges

 Table 4. Novel Vaccine Delivery Systems Market Restraints

 Table 5. Global Novel Vaccine Delivery Systems Revenue by Company (2020-2025) & (US$ Million)

 Table 6. Global Novel Vaccine Delivery Systems Revenue Market Share by Company (2020-2025)

 Table 7. Key Companies Novel Vaccine Delivery Systems Manufacturing Base Distribution and Headquarters

 Table 8. Key Companies Novel Vaccine Delivery Systems Product Type

 Table 9. Key Companies Time to Begin Mass Production of Novel Vaccine Delivery Systems

 Table 10. Global Novel Vaccine Delivery Systems Companies Market Concentration Ratio (CR5 and HHI)

 Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Novel Vaccine Delivery Systems as of 2024)

 Table 12. Mergers & Acquisitions, Expansion Plans

 Table 13. Global Novel Vaccine Delivery Systems Sales Value by Type: 2020 VS 2024 VS 2031 (US$ Million)

 Table 14. Global Novel Vaccine Delivery Systems Sales Value by Type (2020-2025) & (US$ Million)

 Table 15. Global Novel Vaccine Delivery Systems Sales Value by Type (2026-2031) & (US$ Million)

 Table 16. Global Novel Vaccine Delivery Systems Sales Market Share in Value by Type (2020-2025)

 Table 17. Global Novel Vaccine Delivery Systems Sales Market Share in Value by Type (2026-2031)

 Table 18. Global Novel Vaccine Delivery Systems Sales Value by Application: 2020 VS 2024 VS 2031 (US$ Million)

 Table 19. Global Novel Vaccine Delivery Systems Sales Value by Application (2020-2025) & (US$ Million)

 Table 20. Global Novel Vaccine Delivery Systems Sales Value by Application (2026-2031) & (US$ Million)

 Table 21. Global Novel Vaccine Delivery Systems Sales Market Share in Value by Application (2020-2025)

 Table 22. Global Novel Vaccine Delivery Systems Sales Market Share in Value by Application (2026-2031)

 Table 23. Global Novel Vaccine Delivery Systems Sales Value by Region, (2020 VS 2024 VS 2031) & (US$ Million)

 Table 24. Global Novel Vaccine Delivery Systems Sales Value by Region (2020-2025) & (US$ Million)

 Table 25. Global Novel Vaccine Delivery Systems Sales Value by Region (2026-2031) & (US$ Million)

 Table 26. Global Novel Vaccine Delivery Systems Sales Value by Region (2020-2025) & (%)

 Table 27. Global Novel Vaccine Delivery Systems Sales Value by Region (2026-2031) & (%)

 Table 28. Key Countries/Regions Novel Vaccine Delivery Systems Sales Value Growth Trends, (US$ Million): 2020 VS 2024 VS 2031

 Table 29. Key Countries/Regions Novel Vaccine Delivery Systems Sales Value, (2020-2025) & (US$ Million)

 Table 30. Key Countries/Regions Novel Vaccine Delivery Systems Sales Value, (2026-2031) & (US$ Million)

 Table 31. Altaris Capital Partners Basic Information List

 Table 32. Altaris Capital Partners Description and Business Overview

 Table 33. Altaris Capital Partners Novel Vaccine Delivery Systems Products, Services and Solutions

 Table 34. Revenue (US$ Million) in Novel Vaccine Delivery Systems Business of Altaris Capital Partners (2020-2025)

 Table 35. Altaris Capital Partners Recent Developments

 Table 36. Kindeva Drug Delivery Basic Information List

 Table 37. Kindeva Drug Delivery Description and Business Overview

 Table 38. Kindeva Drug Delivery Novel Vaccine Delivery Systems Products, Services and Solutions

 Table 39. Revenue (US$ Million) in Novel Vaccine Delivery Systems Business of Kindeva Drug Delivery (2020-2025)

 Table 40. Kindeva Drug Delivery Recent Developments

 Table 41. Becton Basic Information List

 Table 42. Becton Description and Business Overview

 Table 43. Becton Novel Vaccine Delivery Systems Products, Services and Solutions

 Table 44. Revenue (US$ Million) in Novel Vaccine Delivery Systems Business of Becton (2020-2025)

 Table 45. Becton Recent Developments

 Table 46. Dickinson, Basic Information List

 Table 47. Dickinson, Description and Business Overview

 Table 48. Dickinson, Novel Vaccine Delivery Systems Products, Services and Solutions

 Table 49. Revenue (US$ Million) in Novel Vaccine Delivery Systems Business of Dickinson, (2020-2025)

 Table 50. Dickinson, Recent Developments

 Table 51. Carl Zeiss Foundation Basic Information List

 Table 52. Carl Zeiss Foundation Description and Business Overview

 Table 53. Carl Zeiss Foundation Novel Vaccine Delivery Systems Products, Services and Solutions

 Table 54. Revenue (US$ Million) in Novel Vaccine Delivery Systems Business of Carl Zeiss Foundation (2020-2025)

 Table 55. Carl Zeiss Foundation Recent Developments

 Table 56. Gerresheimer AG Basic Information List

 Table 57. Gerresheimer AG Description and Business Overview

 Table 58. Gerresheimer AG Novel Vaccine Delivery Systems Products, Services and Solutions

 Table 59. Revenue (US$ Million) in Novel Vaccine Delivery Systems Business of Gerresheimer AG (2020-2025)

 Table 60. Gerresheimer AG Recent Developments

 Table 61. Corium International Basic Information List

 Table 62. Corium International Description and Business Overview

 Table 63. Corium International Novel Vaccine Delivery Systems Products, Services and Solutions

 Table 64. Revenue (US$ Million) in Novel Vaccine Delivery Systems Business of Corium International (2020-2025)

 Table 65. Corium International Recent Developments

 Table 66. Inovio Pharmaceuticals Basic Information List

 Table 67. Inovio Pharmaceuticals Description and Business Overview

 Table 68. Inovio Pharmaceuticals Novel Vaccine Delivery Systems Products, Services and Solutions

 Table 69. Revenue (US$ Million) in Novel Vaccine Delivery Systems Business of Inovio Pharmaceuticals (2020-2025)

 Table 70. Inovio Pharmaceuticals Recent Developments

 Table 71. Bioject Medical Technologies Basic Information List

 Table 72. Bioject Medical Technologies Description and Business Overview

 Table 73. Bioject Medical Technologies Novel Vaccine Delivery Systems Products, Services and Solutions

 Table 74. Revenue (US$ Million) in Novel Vaccine Delivery Systems Business of Bioject Medical Technologies (2020-2025)

 Table 75. Bioject Medical Technologies Recent Developments

 Table 76. PharmaJet Basic Information List

 Table 77. PharmaJet Description and Business Overview

 Table 78. PharmaJet Novel Vaccine Delivery Systems Products, Services and Solutions

 Table 79. Revenue (US$ Million) in Novel Vaccine Delivery Systems Business of PharmaJet (2020-2025)

 Table 80. PharmaJet Recent Developments

 Table 81. Retractable Technologies Basic Information List

 Table 82. Retractable Technologies Description and Business Overview

 Table 83. Retractable Technologies Novel Vaccine Delivery Systems Products, Services and Solutions

 Table 84. Revenue (US$ Million) in Novel Vaccine Delivery Systems Business of Retractable Technologies (2020-2025)

 Table 85. Retractable Technologies Recent Developments

 Table 86. Terumo Corporation Basic Information List

 Table 87. Terumo Corporation Description and Business Overview

 Table 88. Terumo Corporation Novel Vaccine Delivery Systems Products, Services and Solutions

 Table 89. Revenue (US$ Million) in Novel Vaccine Delivery Systems Business of Terumo Corporation (2020-2025)

 Table 90. Terumo Corporation Recent Developments

 Table 91. VAXXAS Basic Information List

 Table 92. VAXXAS Description and Business Overview

 Table 93. VAXXAS Novel Vaccine Delivery Systems Products, Services and Solutions

 Table 94. Revenue (US$ Million) in Novel Vaccine Delivery Systems Business of VAXXAS (2020-2025)

 Table 95. VAXXAS Recent Developments

 Table 96. Key Raw Materials Lists

 Table 97. Raw Materials Key Suppliers Lists

 Table 98. Novel Vaccine Delivery Systems Downstream Customers

 Table 99. Novel Vaccine Delivery Systems Distributors List

 Table 100. Research Programs/Design for This Report

 Table 101. Key Data Information from Secondary Sources

 Table 102. Key Data Information from Primary Sources

 Table 103. Business Unit and Senior & Team Lead Analysts

List of Figures

 Figure 1. Novel Vaccine Delivery Systems Product Picture

 Figure 2. Global Novel Vaccine Delivery Systems Sales Value, 2020 VS 2024 VS 2031 (US$ Million)

 Figure 3. Global Novel Vaccine Delivery Systems Sales Value (2020-2031) & (US$ Million)

 Figure 4. Novel Vaccine Delivery Systems Report Years Considered

 Figure 5. Global Novel Vaccine Delivery Systems Players Revenue Ranking (2024) & (US$ Million)

 Figure 6. The 5 and 10 Largest Companies in the World: Market Share by Novel Vaccine Delivery Systems Revenue in 2024

 Figure 7. Novel Vaccine Delivery Systems Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024

 Figure 8. Intradermal Delivery Picture

 Figure 9. Intramuscular Delivery Picture

 Figure 10. Others Picture

 Figure 11. Global Novel Vaccine Delivery Systems Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million)

 Figure 12. Global Novel Vaccine Delivery Systems Sales Value Market Share by Type, 2024 & 2031

 Figure 13. Product Picture of Hospitals & Clinics

 Figure 14. Product Picture of Research Institutes

 Figure 15. Product Picture of Others

 Figure 16. Global Novel Vaccine Delivery Systems Sales Value by Application (2020 VS 2024 VS 2031) & (US$ Million)

 Figure 17. Global Novel Vaccine Delivery Systems Sales Value Market Share by Application, 2024 & 2031

 Figure 18. North America Novel Vaccine Delivery Systems Sales Value (2020-2031) & (US$ Million)

 Figure 19. North America Novel Vaccine Delivery Systems Sales Value by Country (%), 2024 VS 2031

 Figure 20. Europe Novel Vaccine Delivery Systems Sales Value, (2020-2031) & (US$ Million)

 Figure 21. Europe Novel Vaccine Delivery Systems Sales Value by Country (%), 2024 VS 2031

 Figure 22. Asia Pacific Novel Vaccine Delivery Systems Sales Value, (2020-2031) & (US$ Million)

 Figure 23. Asia Pacific Novel Vaccine Delivery Systems Sales Value by Region (%), 2024 VS 2031

 Figure 24. South America Novel Vaccine Delivery Systems Sales Value, (2020-2031) & (US$ Million)

 Figure 25. South America Novel Vaccine Delivery Systems Sales Value by Country (%), 2024 VS 2031

 Figure 26. Middle East & Africa Novel Vaccine Delivery Systems Sales Value, (2020-2031) & (US$ Million)

 Figure 27. Middle East & Africa Novel Vaccine Delivery Systems Sales Value by Country (%), 2024 VS 2031

 Figure 28. Key Countries/Regions Novel Vaccine Delivery Systems Sales Value (%), (2020-2031)

 Figure 29. United States Novel Vaccine Delivery Systems Sales Value, (2020-2031) & (US$ Million)

 Figure 30. United States Novel Vaccine Delivery Systems Sales Value by Type (%), 2024 VS 2031

 Figure 31. United States Novel Vaccine Delivery Systems Sales Value by Application (%), 2024 VS 2031

 Figure 32. Europe Novel Vaccine Delivery Systems Sales Value, (2020-2031) & (US$ Million)

 Figure 33. Europe Novel Vaccine Delivery Systems Sales Value by Type (%), 2024 VS 2031

 Figure 34. Europe Novel Vaccine Delivery Systems Sales Value by Application (%), 2024 VS 2031

 Figure 35. China Novel Vaccine Delivery Systems Sales Value, (2020-2031) & (US$ Million)

 Figure 36. China Novel Vaccine Delivery Systems Sales Value by Type (%), 2024 VS 2031

 Figure 37. China Novel Vaccine Delivery Systems Sales Value by Application (%), 2024 VS 2031

 Figure 38. Japan Novel Vaccine Delivery Systems Sales Value, (2020-2031) & (US$ Million)

 Figure 39. Japan Novel Vaccine Delivery Systems Sales Value by Type (%), 2024 VS 2031

 Figure 40. Japan Novel Vaccine Delivery Systems Sales Value by Application (%), 2024 VS 2031

 Figure 41. South Korea Novel Vaccine Delivery Systems Sales Value, (2020-2031) & (US$ Million)

 Figure 42. South Korea Novel Vaccine Delivery Systems Sales Value by Type (%), 2024 VS 2031

 Figure 43. South Korea Novel Vaccine Delivery Systems Sales Value by Application (%), 2024 VS 2031

 Figure 44. Southeast Asia Novel Vaccine Delivery Systems Sales Value, (2020-2031) & (US$ Million)

 Figure 45. Southeast Asia Novel Vaccine Delivery Systems Sales Value by Type (%), 2024 VS 2031

 Figure 46. Southeast Asia Novel Vaccine Delivery Systems Sales Value by Application (%), 2024 VS 2031

 Figure 47. India Novel Vaccine Delivery Systems Sales Value, (2020-2031) & (US$ Million)

 Figure 48. India Novel Vaccine Delivery Systems Sales Value by Type (%), 2024 VS 2031

 Figure 49. India Novel Vaccine Delivery Systems Sales Value by Application (%), 2024 VS 2031

 Figure 50. Novel Vaccine Delivery Systems Industrial Chain

 Figure 51. Novel Vaccine Delivery Systems Manufacturing Cost Structure

 Figure 52. Channels of Distribution (Direct Sales, and Distribution)

 Figure 53. Bottom-up and Top-down Approaches for This Report

 Figure 54. Data Triangulation

 Figure 55. Key Executives Interviewed


We can offer customized data and information to meet our clients need.

This report focuses on:

► Intelligent insights to take informed business decisions.

► Qualitative and quantitative analysis of the market.

► Market size and forecasts from 2024 to 2030.

► Opportunities for expansion and in-depth market analysis.

► Segmentation and regional revenue forecasts.

► Analysis of the market share and competitive landscape.

► Strategic recommendations for future growth.


You'll also receive:

► A comprehensive market research report in PDF or PPT formats.

► Access to our analysts to learn more about the report and get answers to your specific business questions.

► The option to customize the report to meet your specific needs, such as adding more countries or regions or developing abusiness case to launch a new product.


Contact us today to learn more and get sample report.


Our Research Reports Look Like This
Pragma Market Research Sample

Covid-19 Impact Duns and Brad Badge
up